Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Prescient Therapeutics Ltd

PTX.AX ✗ NOT COMPLIANT ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.05

▲ +4.62%

Market Cap $51.15M · Vol 1.52M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$51.15M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

N/A

YoY

RSI (14)

38.89

Momentum

Beta

0.33

vs Market

52W High

$0.09

40.94% below

52W Low

$0.03

83.35% above

Volume

1.52M

Avg 1.00M

P/B

4.52

Price-to-book

ROE

N/A

Return on equity

Free Float

89.43%

Public shares

Shariah Compliance8 STANDARDS

✗ Prescient Therapeutics Ltd (PTX.AX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PTX.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

-20.93%

-2.86%

+17.24%

YTD

-19.05%

+65.85%

+11.58%

-69.78%

Financials & Valuation

TTM · Annual

Total Revenue	$95.82K
Net Income	$-4,845,112.00
Revenue Growth (YoY)	+332.59%
Gross Margin	100.00%
Operating Margin	-7,547.29%
Net Profit Margin	-5,056.31%
ROE	N/A
ROA · ROIC	-45.41% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	452.13
P/B	4.52
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	1.05B

Technical Indicators

50-Day SMA	$0.06
200-Day SMA	$0.05
RSI (14)	38.89
Beta	0.33
52-Week High	$0.09
52-Week Low	$0.03

Volume Today	1.52M
Avg Daily Volume (30D)	1.00M
Relative Volume	1.52x
Volatility (10D)	37.44
Volatility (30D)	47.97
Free Float	89.43%

Analyst Consensus

N/A

Current Price $0.05

Mean Target N/A

52W Low$0.03 52W High$0.09

Current

Target

$0.03 $0.09

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG001S9SH09

ISINAU000000PTX3

CountryAustralia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LONN.S Lonza Group AG -0.71% ONC BeOne Medicines AG +1.38% 068270.KS Celltrion, Inc. -1.44% ABVX Abivax SA +2.32% ABVX.PA Abivax SA +1.00%

Company Profile

Prescient Therapeutics Limited is a clinical-stage oncology company. It is engaged in developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, CellPryme-M, and OmniCAR. PTX-100 is a first-in-class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. PTX-100 is in a Phase 2a clinical study in refractory/relapsed Cutaneous T Cell Lymphoma with Fast Track Designation. CellPryme-M is a high-performance cell therapy enhancement platform that can improve CAR-T efficacy. The CellPryme platform consists of two distinct components which can be used separately but have significant synergies when used together. OmniCAR is a universal CAR platform that is controllable, with plug and play capabilities to enable a wider range of cancers to be targeted. OmniCAR enables controllable T-cell activity and multiantigen targeting with a single cell product.